Icecure Medical Ltd Ord (ICCM)

$0.37 -0.02 (-3.92%)
Market Cap 27.41M
Revenue (ttm) 3.38M
Net Income (ttm) -15.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -445.56%
Debt to Equity Ratio 0.00
Volume 847,500
Avg Vol 365,314
Day's Range N/A - N/A
Shares Out 73.12M
Stochastic %K 1%
Beta 0.29
Analysts Strong Sell
Price Target $3.00

Company Profile

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic...

Industry: Medical Devices
Sector: Healthcare
Phone: 972 4 623 0333
Fax: 972 4 623 0222
Address:
7 Ha’Eshel Street, PO Box 3163, Caesarea, Israel
Lirik
Lirik Mar. 30 at 12:33 AM
$ICCM the latest 4 million dollar raise/dilution wasn’t enough. They need 10x that with their current employee count of 70 and to pay for research requirements. The only good news is they have made some deals with the largest hospital chains in the US. Sales will be increasing drastically quarter to quarter but will it be enough to move the share price significantly?
0 · Reply
Logan93
Logan93 Mar. 27 at 3:26 PM
$ICCM “According to the Notice, the Company has until May 11, 2026, to regain compliance with the minimum bid price requirement.” From 11/14 press release. Question is do they go for another 180-days or reverse split before the deadline? I honestly don’t see a path for them to close above a buck for ten consecutive days by May 11th.
1 · Reply
Lstreak
Lstreak Mar. 27 at 1:37 PM
$ICCM This isn't going anywhere. Sad to say the only thing you can bank on here is a reverse stock split.
0 · Reply
santaya
santaya Mar. 27 at 6:07 AM
$ICCM trash
0 · Reply
Socaldodgerfan8
Socaldodgerfan8 Mar. 27 at 2:32 AM
$ICCM Damn, I felt like I had made such a good move buying this at .71 a year and a half ago. “1st qtr FDA approval” they said. Then it dragged. FDA approval turned out to just be a bag of dicks, and it’s been raining dicks ever since. Thank you sir! May I have another?!
1 · Reply
Lyn30
Lyn30 Mar. 26 at 9:00 PM
$ICCM still holding but very disappointed Every ili stock do the same . In market if one do mistake have to pay by 💰💰💰
0 · Reply
justme_DC
justme_DC Mar. 26 at 6:48 PM
$ICCM Agreed. With this announcement, most likely there is no 'magical and huge' nesr term announcement that is suddenly going to make this skyrocket. Probably best to wait and let the dust settle. The idea of patience doesn't just apply to after you have bought, but also before you buy.
0 · Reply
Logan93
Logan93 Mar. 26 at 5:11 PM
$ICCM It looks like a reverse split is all but inevitable now. Too bad they didn’t have any material news to prop up the share price a bit before diluting. I might jump back in after they reach compliance and the dust settles. On watch for now.
0 · Reply
Leemarvin70
Leemarvin70 Mar. 26 at 4:56 PM
$ICCM para que comprar ahora?. Esto hará RS y bajará un 30-50%. Después de eso ya veremos
2 · Reply
StStephen72
StStephen72 Mar. 26 at 2:35 PM
$ICCM Bingo . We knew they were low on cash. Hmmm. Shared and 2 sets of warrants. I'm going to place a buy at .35. Pete
0 · Reply
Latest News on ICCM
IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

Mar 26, 2026, 8:00 AM EDT - 3 days ago

IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

Mar 25, 2026, 8:30 AM EDT - 4 days ago

IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

IceCure Appoints Meir Peleg as Chief Financial Officer

Mar 24, 2026, 8:30 AM EDT - 5 days ago

IceCure Appoints Meir Peleg as Chief Financial Officer

IceCure Reports 2025 Full Year Financial & Operational Results

Mar 17, 2026, 8:30 AM EDT - 12 days ago

IceCure Reports 2025 Full Year Financial & Operational Results

U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

Mar 11, 2026, 8:30 AM EDT - 18 days ago

U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

Mar 10, 2026, 8:30 AM EDT - 19 days ago

IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer

Mar 9, 2026, 8:30 AM EDT - 20 days ago

American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer

IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas

Mar 2, 2026, 8:30 AM EST - 27 days ago

IceCure Medical Reports Independent Study Published in PLOS One Demonstrating ProSense® Cryoablation Safe and Effective in Treatment of Breast Fibroadenomas

IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026

Feb 23, 2026, 8:30 AM EST - 4 weeks ago

IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026

IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation

Feb 19, 2026, 8:30 AM EST - 5 weeks ago

IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense®, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation

IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®

Feb 11, 2026, 8:30 AM EST - 6 weeks ago

IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

Feb 9, 2026, 4:30 PM EST - 6 weeks ago

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

Jan 28, 2026, 8:30 AM EST - 2 months ago

IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

Jan 12, 2026, 8:30 AM EST - 2 months ago

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

Dec 17, 2025, 8:30 AM EST - 3 months ago

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

Dec 10, 2025, 8:30 AM EST - 3 months ago

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

Dec 5, 2025, 8:30 AM EST - 4 months ago

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

Nov 19, 2025, 8:54 AM EST - 4 months ago

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

Nov 18, 2025, 8:30 AM EST - 4 months ago

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Nov 14, 2025, 4:30 PM EST - 4 months ago

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

Nov 12, 2025, 8:30 AM EST - 4 months ago

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

Nov 10, 2025, 8:30 AM EST - 4 months ago

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

Nov 3, 2025, 8:30 AM EST - 5 months ago

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

Oct 13, 2025, 8:30 AM EDT - 5 months ago

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

IceCure Medical to Attend the 2025 Maxim Growth Summit

Oct 9, 2025, 8:30 AM EDT - 6 months ago

IceCure Medical to Attend the 2025 Maxim Growth Summit

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

Oct 3, 2025, 12:28 PM EDT - 6 months ago

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Oct 3, 2025, 12:19 PM EDT - 6 months ago

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

Sep 30, 2025, 8:30 AM EDT - 6 months ago

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

Sep 22, 2025, 8:30 AM EDT - 6 months ago

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

Sep 18, 2025, 8:30 AM EDT - 6 months ago

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Sep 15, 2025, 8:30 AM EDT - 6 months ago

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

Sep 8, 2025, 8:30 AM EDT - 7 months ago

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

Sep 4, 2025, 8:30 AM EDT - 7 months ago

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

IceCure Reports Financial & Operational Results for the First Half of 2025

Aug 13, 2025, 8:30 AM EDT - 8 months ago

IceCure Reports Financial & Operational Results for the First Half of 2025

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

Aug 6, 2025, 8:30 AM EDT - 8 months ago

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

Jul 29, 2025, 9:00 AM EDT - 8 months ago

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

Jul 25, 2025, 9:00 AM EDT - 8 months ago

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

Jul 24, 2025, 9:00 AM EDT - 8 months ago

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

IceCure Announces Commencement of Rights Offering

Jul 10, 2025, 8:00 AM EDT - 9 months ago

IceCure Announces Commencement of Rights Offering

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

Jul 3, 2025, 8:30 AM EDT - 9 months ago

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

IceCure Announces Record Date for Rights Offering for Up to $10 Million

Jun 25, 2025, 9:23 AM EDT - 9 months ago

IceCure Announces Record Date for Rights Offering for Up to $10 Million

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

Jun 9, 2025, 8:30 AM EDT - 10 months ago

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

IceCure Medical Reports First Quarter 2025 Financial Results

May 28, 2025, 8:30 AM EDT - 10 months ago

IceCure Medical Reports First Quarter 2025 Financial Results

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

May 21, 2025, 8:30 AM EDT - 11 months ago

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

May 6, 2025, 8:30 AM EDT - 11 months ago

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

Apr 30, 2025, 8:30 AM EDT - 11 months ago

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

Apr 28, 2025, 8:30 AM EDT - 11 months ago

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

Apr 22, 2025, 8:30 AM EDT - 1 year ago

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

Mar 27, 2025, 8:30 AM EDT - 1 year ago

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

Mar 24, 2025, 8:30 AM EDT - 1 year ago

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

Lirik
Lirik Mar. 30 at 12:33 AM
$ICCM the latest 4 million dollar raise/dilution wasn’t enough. They need 10x that with their current employee count of 70 and to pay for research requirements. The only good news is they have made some deals with the largest hospital chains in the US. Sales will be increasing drastically quarter to quarter but will it be enough to move the share price significantly?
0 · Reply
Logan93
Logan93 Mar. 27 at 3:26 PM
$ICCM “According to the Notice, the Company has until May 11, 2026, to regain compliance with the minimum bid price requirement.” From 11/14 press release. Question is do they go for another 180-days or reverse split before the deadline? I honestly don’t see a path for them to close above a buck for ten consecutive days by May 11th.
1 · Reply
Lstreak
Lstreak Mar. 27 at 1:37 PM
$ICCM This isn't going anywhere. Sad to say the only thing you can bank on here is a reverse stock split.
0 · Reply
santaya
santaya Mar. 27 at 6:07 AM
$ICCM trash
0 · Reply
Socaldodgerfan8
Socaldodgerfan8 Mar. 27 at 2:32 AM
$ICCM Damn, I felt like I had made such a good move buying this at .71 a year and a half ago. “1st qtr FDA approval” they said. Then it dragged. FDA approval turned out to just be a bag of dicks, and it’s been raining dicks ever since. Thank you sir! May I have another?!
1 · Reply
Lyn30
Lyn30 Mar. 26 at 9:00 PM
$ICCM still holding but very disappointed Every ili stock do the same . In market if one do mistake have to pay by 💰💰💰
0 · Reply
justme_DC
justme_DC Mar. 26 at 6:48 PM
$ICCM Agreed. With this announcement, most likely there is no 'magical and huge' nesr term announcement that is suddenly going to make this skyrocket. Probably best to wait and let the dust settle. The idea of patience doesn't just apply to after you have bought, but also before you buy.
0 · Reply
Logan93
Logan93 Mar. 26 at 5:11 PM
$ICCM It looks like a reverse split is all but inevitable now. Too bad they didn’t have any material news to prop up the share price a bit before diluting. I might jump back in after they reach compliance and the dust settles. On watch for now.
0 · Reply
Leemarvin70
Leemarvin70 Mar. 26 at 4:56 PM
$ICCM para que comprar ahora?. Esto hará RS y bajará un 30-50%. Después de eso ya veremos
2 · Reply
StStephen72
StStephen72 Mar. 26 at 2:35 PM
$ICCM Bingo . We knew they were low on cash. Hmmm. Shared and 2 sets of warrants. I'm going to place a buy at .35. Pete
0 · Reply
grandpa_dirt
grandpa_dirt Mar. 26 at 2:27 PM
$ICCM Crazy that companies trying to save lives struggle to find funding, while their entire yearly operational budget could be covered by the price of a handful of missiles that their government has no problem paying for. I really should be investing in "defense" contractors instead.
1 · Reply
MomentumKiller
MomentumKiller Mar. 26 at 2:24 PM
$ICCM this is an amazing cancer treatment that should be fast tracked through FDA and all the stock does is go down!!
2 · Reply
Socaldodgerfan8
Socaldodgerfan8 Mar. 26 at 2:12 PM
$ICCM Gut punch
0 · Reply
Aimoney
Aimoney Mar. 26 at 2:04 PM
$ICCM come closer
0 · Reply
Planetpaprika
Planetpaprika Mar. 26 at 1:43 PM
$ICCM entered into securities purchase agreements with healthcare-focused institut. investors to sell 8M ordinary shares at $0.50 each in a registered direct offering. Gross proceeds expected to be about $4M. Additionally, in the private placement, ICCM plans to issue Series B & Series C warrants covering up to 8M shares each. The warrants will have an exercise price of $0.55 per share, be exercisable immediately, with Series B warrants expiring in 5 years and Series C warrants in 1 year from issuance. The offering is expected to close on or about March 27, 2026.
0 · Reply
Lstreak
Lstreak Mar. 26 at 1:32 PM
$ICCM Will we see .30 today with a reverse split to follow later on?
0 · Reply
Wats_Up
Wats_Up Mar. 26 at 1:29 PM
$ICCM Only question now is RS numbers. 1 for 50, 1 for 100?
0 · Reply
Biorocksme
Biorocksme Mar. 26 at 12:51 PM
$ICCM They needed the funds badly if you paid attention. Dilution is the solution on penny stocks. It is their blood
0 · Reply
Planetpaprika
Planetpaprika Mar. 26 at 12:05 PM
$ICCM https://ir.icecure-medical.com/news-events/press-releases/detail/216/icecure-announces-pricing-of-4-0-million-registered-direct-offering-and-concurrent-private-placement
0 · Reply
Leemarvin70
Leemarvin70 Mar. 26 at 11:07 AM
$ICCM pués todavía te queda la mejor noticia....
0 · Reply
alinandad
alinandad Mar. 25 at 11:48 PM
$ICCM It’d be great for Jane Street to sell their insignificant share count now.
0 · Reply
grandpa_dirt
grandpa_dirt Mar. 25 at 11:23 PM
$ICCM I'm starting to think Big Chemo is trying to kill this company.
1 · Reply